PCM
IRWD icon

Piermont Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Piermont Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-41,802
Closed -$560K – 238
2015
Q1 		$560K Buy
41,802
+14,137
+51% +$185K 0.17% 150
2014
Q4 		$355K Hold
27,665
– – 0.13% 150
2014
Q3 		$300K Buy
+27,665
New +$317K 0.12% 160

Other funds holding IRWD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Piermont Capital Management's IRWD Position: Q2 2015 in Review

Piermont Capital Management sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2015, closing a stake of 41,802 shares — an estimated $560K sold.

Piermont Capital Management first reported a position in IRWD in Q3 2014 and held it in 3 quarters. The position peaked at $560K in Q1 2015. 137 funds tracked by Wall St. Rank hold IRWD as of Q2 2015.

  • Piermont Capital Management reported no remaining Ironwood Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Piermont Capital Management sold 41,802 Ironwood Pharmaceuticals shares in Q2 2015, an estimated $560K.
  • Piermont Capital Management first reported a position in Ironwood Pharmaceuticals in Q3 2014 and held it in 3 quarters.
  • Piermont Capital Management's Ironwood Pharmaceuticals position peaked at $560K in Q1 2015.
  • 137 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2015.

Based on Piermont Capital Management's 13F filing for Q2 2015, filed 13 Aug 2015.